Flexible Solutions International Earnings Call Transcripts
Fiscal Year 2026
-
Q2 sales declined 14% YoY and results swung to a $1.91M loss, partly due to food and factory scale-up costs. Management expects Q3 profitability and faster Q4 growth as food contracts ramp and Panama improves.
-
Q1 2026 saw 11% sales growth and a reduced net loss, with major food-grade contracts ramping up and Panama production optimizing international logistics. Profits are expected to rise in the second half of 2026, despite ongoing tariff and supply chain challenges.
Fiscal Year 2025
-
Revenue was flat year-over-year at $38.51M, with net profit down to $787K due to ramp-up costs for new food contracts and Panama factory. Major food contracts are ramping up, with margins expected to improve and profits to rise sharply in the second half of 2026.
-
Q3 2025 revenue rose 13% year-over-year, but one-time ramp-up costs for new food contracts and the Panama plant led to a net loss. EMP division performed strongly, while agriculture sales lagged. Profits are expected to rebound in Q1 2026 as new contracts scale up.
-
Q2 2025 saw 8% sales growth and a net profit of $2.03M, driven by a $2.5M R&D contract. Two major food-grade contracts were secured, with significant revenue expected from Q4 2025. Panama plant will reduce tariff exposure and support international growth.
-
Q1 2025 saw a 19% year-over-year revenue decline and a net loss, mainly due to inventory reductions and upfront costs for new contracts and the Panama factory. Growth is expected in the second half of 2025, with major new food-grade revenue anticipated by early 2026.
Fiscal Year 2024
-
Revenue held steady at $38.23M in 2024, with net profit rising to $3.04M. Major CapEx is planned for a new food-grade contract, and a Panama plant will reduce tariff exposure. Growth is expected in late 2025, driven by new product launches and improved logistics.
-
Q3 2024 saw 7% sales growth and a return to profitability, driven by strong NCS and EMP division performance and operational streamlining. New food and nutraceutical products are nearing commercialization, with potential to double revenue if successful.
-
Q2 2024 saw 2% sales growth and a 59% profit increase, driven by strong food and international sales. The Florida LLC was sold for $2M cash plus $800K/year, with an exclusive supply agreement retained. Growth is expected to continue, especially in food and international markets.